<?xml version="1.0"?>
<?xml-stylesheet type='text/xsl' href='../../ld1.xsl'?>
<LOBBYINGDISCLOSURE1>
   <imported>N</imported>
   <pages>2</pages>
   <regType>3</regType>
   <organizationName>POLICY DIRECTIONS INC.</organizationName>
   <prefix></prefix>
   <firstName></firstName>
   <lastName></lastName>
   <address1>818 CONNECTICUT AVENUE, NW, #950</address1>
   <address2></address2>
   <city>WASHINGTON, DC</city>
   <state>DC</state>
   <zip>20006</zip>
   <zipext></zipext>
   <country>USA</country>
   <principal_city></principal_city>
   <principal_state></principal_state>
   <principal_zip></principal_zip>
   <principal_zipext></principal_zipext>
   <principal_country></principal_country>
   <registrantGeneralDescription>Government Relations</registrantGeneralDescription>
   <selfSelect>N</selfSelect>
   <clientName>QRxPHARMA LIMITED</clientName>
   <clientAddress>1430 Route 206 North, Suite 230</clientAddress>
   <clientCity>Bedminster</clientCity>
   <clientState>NJ</clientState>
   <clientZip>07921</clientZip>
   <clientZipExt></clientZipExt>
   <clientCountry>USA</clientCountry>
   <prinClientCity>North Sydney</prinClientCity>
   <prinClientState></prinClientState>
   <prinClientZip>2060</prinClientZip>
   <prinClientZipExt></prinClientZipExt>
   <prinClientCountry>AUS</prinClientCountry>
   <clientGeneralDescription>Specialty pharmaceutical company</clientGeneralDescription>
   <senateID>31747-1004505</senateID>
   <houseID>321120088</houseID>
   <lobbyists>
      <lobbyist>
         <lobbyistFirstName>FRANKIE L.</lobbyistFirstName>
         <lobbyistLastName>TRULL</lobbyistLastName>
         <lobbyistSuffix></lobbyistSuffix>
         <coveredPosition></coveredPosition>
         <lobbyistNew>Y</lobbyistNew>
      </lobbyist>
      <lobbyist>
         <lobbyistFirstName>JILL HOMER </lobbyistFirstName>
         <lobbyistLastName>STEWART</lobbyistLastName>
         <lobbyistSuffix></lobbyistSuffix>
         <coveredPosition>Rep. Peter Visclosky - Legislative Director</coveredPosition>
         <lobbyistNew>Y</lobbyistNew>
      </lobbyist>
      <lobbyist>
         <lobbyistFirstName>"</lobbyistFirstName>
         <lobbyistLastName>"</lobbyistLastName>
         <lobbyistSuffix></lobbyistSuffix>
         <coveredPosition>Rep. Robert Weygand, Staff Assistant</coveredPosition>
         <lobbyistNew>Y</lobbyistNew>
      </lobbyist>
      <lobbyist>
         <lobbyistFirstName>"</lobbyistFirstName>
         <lobbyistLastName>"</lobbyistLastName>
         <lobbyistSuffix></lobbyistSuffix>
         <coveredPosition>Sen. Dianne Feinstein, Staff Assistant</coveredPosition>
         <lobbyistNew>Y</lobbyistNew>
      </lobbyist>
      <lobbyist>
         <lobbyistFirstName>"</lobbyistFirstName>
         <lobbyistLastName>"</lobbyistLastName>
         <lobbyistSuffix></lobbyistSuffix>
         <coveredPosition>Rep. Gary Condit, Intern</coveredPosition>
         <lobbyistNew>Y</lobbyistNew>
      </lobbyist>
   </lobbyists>
   <alis>
      <ali_Code>MED</ali_Code>
      <ali_Code>ALC</ali_Code>
      <ali_Code></ali_Code>
      <ali_Code></ali_Code>
      <ali_Code></ali_Code>
      <ali_Code></ali_Code>
      <ali_Code></ali_Code>
      <ali_Code></ali_Code>
      <ali_Code></ali_Code>
   </alis>
   <specific_issues>Improved post-surgical pain medication.
Prescription drug abuse deterent technology.</specific_issues>
   <affiliatedUrl></affiliatedUrl>
   <affiliatedOrgs>
      <affiliatedOrg>
         <affiliatedOrgName></affiliatedOrgName>
         <affiliatedOrgAddress></affiliatedOrgAddress>
         <affiliatedOrgCity></affiliatedOrgCity>
         <affiliatedOrgState></affiliatedOrgState>
         <affiliatedOrgZip></affiliatedOrgZip>
         <affiliatedOrgCountry></affiliatedOrgCountry>
         <affiliatedPrinOrgCity></affiliatedPrinOrgCity>
         <affiliatedPrinOrgState></affiliatedPrinOrgState>
         <affiliatedPrinOrgCountry></affiliatedPrinOrgCountry>
      </affiliatedOrg>
      <affiliatedOrg>
         <affiliatedOrgName></affiliatedOrgName>
         <affiliatedOrgAddress></affiliatedOrgAddress>
         <affiliatedOrgCity></affiliatedOrgCity>
         <affiliatedOrgState></affiliatedOrgState>
         <affiliatedOrgZip></affiliatedOrgZip>
         <affiliatedOrgCountry></affiliatedOrgCountry>
         <affiliatedPrinOrgCity></affiliatedPrinOrgCity>
         <affiliatedPrinOrgState></affiliatedPrinOrgState>
         <affiliatedPrinOrgCountry></affiliatedPrinOrgCountry>
      </affiliatedOrg>
      <affiliatedOrg>
         <affiliatedOrgName></affiliatedOrgName>
         <affiliatedOrgAddress></affiliatedOrgAddress>
         <affiliatedOrgCity></affiliatedOrgCity>
         <affiliatedOrgState></affiliatedOrgState>
         <affiliatedOrgZip></affiliatedOrgZip>
         <affiliatedOrgCountry></affiliatedOrgCountry>
         <affiliatedPrinOrgCity></affiliatedPrinOrgCity>
         <affiliatedPrinOrgState></affiliatedPrinOrgState>
         <affiliatedPrinOrgCountry></affiliatedPrinOrgCountry>
      </affiliatedOrg>
   </affiliatedOrgs>
   <foreignEntities>
      <foreignEntity>
         <name>QRxPharma Limited</name>
         <address>Level 1, 194 Miller Street</address>
         <city>North Sydney 2060</city>
         <state></state>
         <country>AUS</country>
         <prinCity>North Sydney NSW 2060</prinCity>
         <prinState></prinState>
         <prinCountry>AUS</prinCountry>
         <contribution>0.00</contribution>
         <ownership_Percentage>100</ownership_Percentage>
      </foreignEntity>
      <foreignEntity>
         <name></name>
         <address></address>
         <city></city>
         <state></state>
         <country></country>
         <prinCity></prinCity>
         <prinState></prinState>
         <prinCountry></prinCountry>
         <contribution></contribution>
         <ownership_Percentage></ownership_Percentage>
      </foreignEntity>
   </foreignEntities>
   <reportYear>2014</reportYear>
   <reportType>RA</reportType>
   <effectiveDate>01/01/2014</effectiveDate>
   <printedName>FRANKIE L. TRULL, PRESIDENT &amp; CEO</printedName>
   <signedDate>01/16/2014</signedDate>
</LOBBYINGDISCLOSURE1>